Johnson & Johnson (JNJ) EBITDA Margin: 43.59%
Is Johnson & Johnson’s EBITDA margin high or low?
Johnson & Johnson's EBITDA margin of 43.59% is 34% above its 5-year average of 32.51%, near the high end of its 5-year range (27.38%–43.59%).
The EBITDA margin for Johnson & Johnson (JNJ) is 43.59% as of Tuesday, June 9, 2026. It is above its 12-month average by 21.95% (35.75%).
JNJ EBITDA Margin Chart
JNJ Average EBITDA Margin Chart
JNJ Current vs Average EBITDA Margin Chart
JNJ EBITDA Margin Metrics
EBITDA MARGIN
43.59%
EBITDA MARGIN AVG TTM
35.75%
EBITDA MARGIN AVG 3Y
33.03%
EBITDA MARGIN AVG 5Y
32.51%
EBITDA MARGIN AVG 10Y
32.36%
EBITDA MARGIN AVG 15Y
31.39%
EBITDA MARGIN AVG 20Y
30.98%
CURRENT VS TTM AVG
+21.95%
CURRENT VS 3Y AVG
+31.96%
CURRENT VS 5Y AVG
+34.07%
CURRENT VS 10Y AVG
+34.71%
CURRENT VS 15Y AVG
+38.87%
CURRENT VS 20Y AVG
+40.69%
JNJ Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | — | 43.59% | 35.75% | 33.03% | 32.51% |
| Pfizer Inc. (PFE) | $146.48B | 24.12% | 26.30% | 27.39% | 29.84% |
| Merck & Co., Inc. (MRK) | $295.39B | 45.17% | 42.62% | 33.17% | 32.32% |
| AbbVie Inc. (ABBV) | $398.27B | 28.82% | 27.64% | 32.13% | 33.01% |
| Eli Lilly and Company (LLY) | $1.08T | 42.86% | 38.34% | 33.03% | 32.81% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 30.18% | 18.37% | 30.35% | 29.39% |
Margin Comparison
Gross Margin
72.8%
EBITDA Margin
43.6%
Operating Margin
27.2%
Net Margin
28.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Johnson & Johnson EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson EBITDA Margin FAQ
- What is the EBITDA margin for Johnson & Johnson (JNJ)?
- The EBITDA margin for JNJ stock is 43.59%.
- Is Johnson & Johnson's EBITDA margin high or low?
- Johnson & Johnson's EBITDA margin of 43.59% is 34% above its 5-year average of 32.51%, near the high end of its 5-year range (27.38%–43.59%).
- What is the TTM average EBITDA margin for Johnson & Johnson (JNJ)?
- The TTM average EBITDA margin for JNJ stock is 35.75%.
- What is the 3Y average EBITDA margin for Johnson & Johnson (JNJ)?
- The 3Y average EBITDA margin for JNJ stock is 33.03%.
- What is the 5Y average EBITDA margin for Johnson & Johnson (JNJ)?
- The 5Y average EBITDA margin for JNJ stock is 32.51%.
- What is the 10Y average EBITDA margin for Johnson & Johnson (JNJ)?
- The 10Y average EBITDA margin for JNJ stock is 32.36%.
- What is the 15Y average EBITDA margin for Johnson & Johnson (JNJ)?
- The 15Y average EBITDA margin for JNJ stock is 31.39%.
- What is the 20Y average EBITDA margin for Johnson & Johnson (JNJ)?
- The 20Y average EBITDA margin for JNJ stock is 30.98%.
Johnson & Johnson EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-28 | 43.59% |
| 2024-12-29 | 27.90% |
| 2023-12-31 | 27.38% |
| 2023-01-01 | 33.26% |
| 2022-01-02 | 33.97% |
| 2021-01-03 | 28.98% |
| 2019-12-31 | 30.05% |
| 2018-12-31 | 31.79% |
| 2017-12-31 | 31.72% |
| 2016-12-31 | 33.78% |
| 2015-12-31 | 33.53% |
| 2014-12-31 | 33.62% |
| 2013-12-31 | 28.13% |
| 2012-12-31 | 26.74% |
| 2011-12-31 | 24.74% |
| 2010-12-31 | 33.03% |
| 2009-12-31 | 30.66% |
| 2008-12-31 | 31.68% |
| 2007-12-31 | 26.77% |
| 2006-12-31 | 29.79% |
| 2005-12-31 | 29.54% |
| 2004-12-31 | 30.58% |
| 2003-12-31 | 30.43% |
| 2002-12-31 | 31.24% |
| 2001-12-31 | 29.37% |
| 2000-12-31 | 28.13% |
| 1999-12-31 | 26.76% |
| 1998-12-31 | 26.31% |
| 1997-12-31 | 25.14% |
| 1996-12-31 | 24.57% |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato